Author

S. S. Dhar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

M. Lee· 3 shared A. Rizvi· 1 shared B. Gu· 1 shared B. Kim· 1 shared C. Brown· 1 shared C. M. Rudin· 1 shared C. Zod· 1 shared D.-W. Kim· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. Lee

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of lysine demethylation and oxidative phosphorylation

S. S. Dhar, C. Brown, A. Rizvi, L. Reed, S. Kotla, C. Zod, J. Abraham, J.-I. Abe, V. Rajaram, K. Chen, M. Lee

This study shows that heterozygous Kmt2d loss promotes medulloblastoma by enhancing tumor-promoting programs and that combining LSD1 inhibition with oxidative phosphorylation blockade reduces tumorigenicity.

bioRxiv · Oct 29, 2023 · PreprintCancer Biology

Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer

Y. Seo, S. Zhang, J. Jang, K.-P. Ko, K.-B. Kim, Y. Huang, D.-W. Kim, B. Kim, G. Zou, J. Zhang, S. Jun, W. Chu, N. A. Kirk, Y. E. Hwang, Y. H. Ban, , J.-I. Park

This study shows that CRACD, an actin regulator, suppresses neuroendocrine plasticity and immune evasion in SCLC by modulating NOTCH1 and EZH2 pathways, suggesting EZH2 blockade as a potential therapy.

bioRxiv · Feb 15, 2023Cancer Biology

Super-enhancer impairment is a link between MLL4 inactivated lung tumors and their vulnerability to glycolysis pathway inhibition

H. Alam, M. Tang, M. Maitituoheti, S. S. Dhar, S. Amin, B. Gu, T.-Y. Chen, Y.-H. Lin, J. Chen, F. Muller, F. J. DeMayo, L. Baseler, K. Rai, M. Lee

The paper shows that MLL4 loss in lung cancer promotes glycolysis and that inhibiting glycolysis selectively targets MLL4-mutant lung tumors.

bioRxiv · Dec 28, 2018 · PreprintCancer Biology